Intracellular ROS levels in liver cancer cells in response to the DCA treatment significantly increased following a 1-h DCA treatment compared to the control (p < 0.001 for HepG2 and p = 0.07 for PLC/PRF5,Figure 5A), and by metformin compared to the control (p = 0.02 for HepG2 and p < 0.001 for PLC/PRF5, Figure 5A). The gene discussed is HSPG2; the disease is liver cancer.